Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Abstract Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β2−agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single doses of navafenterol were investigated in pati...

Full description

Bibliographic Details
Main Authors: Dave Singh, Victor Balaguer, Carol Astbury, Ulrika Wählby-Hamrén, Eulalia Jimenez, Beatriz Seoane, Cristina Villarroel, Alejhandra Lei, Ajay Aggarwal, Ioannis Psallidas
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Respiratory Research
Subjects:
Bronchodilator
COPD
MABA
Dual-pharmacology muscarinic receptor antagonist β2-adrenoceptor agonist
Safety
Pharmacokinetics
Online Access:http://link.springer.com/article/10.1186/s12931-020-01347-7

Internet

http://link.springer.com/article/10.1186/s12931-020-01347-7

Similar Items